menu search

Processa pharmaceuticals to present pcs12852 gastroparesis results at the digestive disease week 2023 annual meeting

pcs12852 Shown to be Safe and Efficacious in Phase 2 Proof-of-Concept Trial in Gastroparesis Patients <...

April 28, 2023, 12:15 pm

Processa pharmaceuticals to present pcs12852 gastroparesis results at the digestive disease week 2023 annual meeting

HANOVER, MD, April 28, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage ...

April 28, 2023, 8:15 am


Search within

Pages Search Results: